Abstract:Adoptive immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has exhibited impressive clinical efficacy in treating B-cell malignancies. However, the potency of CAR-T cells carriethe potential for significant on-target/off-tumor toxicities when target antigens are shared with healthy cells, necessitating the development of complementary safety measures. In this context, there is a need to selectively eliminate therapeutically administered CAR-T cells, especially to revert long-term CAR-T cell-related side effects. To address this, we have developed an effective cellular-based safety mechanism to specifically target and eliminate the transferred CAR-T cells. As proof-of-principle, we have designed a secondary CAR ( anti -CAR CAR) capable of recognizing a short peptide sequence (Strep-tag II) incorporated into the hinge domain of an anti -CD19 CAR. In in vitro experiments, these anti -CAR CAR-T cells have demonstrated antigen-specific cytokine release and cytotoxicity when co-cultured with anti -CD19 CAR-T cells. Moreover, in both immunocompromised and immunocompetent mice, we observed the successful depletion of anti -CD19 CAR-T cells when administered concurrently with anti -CAR CAR-T cells. We have also demonstrated the efficacy of this safeguard mechanism in a clinically relevant animal model of B-cell aplasia induced by CD19 CAR treatment, where this side effect was reversed upon anti -CAR CAR-T cells infusion. Notably, efficient B-cell recovery occurred even in the absence of any pre-conditioning regimens prior anti -CAR CAR-T cells transfer, thus enhancing its practical applicability. In summary, we developed a robust cellular safeguard system for selective in vivo elimination of engineered T cells, offering a promising solution to address CAR-T cell-related on-target/off-tumor toxicities.

Chimeric HLA antibody receptor T cell therapy for humoral transplant rejection

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

Helper T Cell (CD4 + ) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity

Single-Cell Heterogeneity Restorative Chimeric Engineering Nanoparticles for Alleviating Antibody-Mediated Allograft Injury.

Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

Translating B cell immunology to the treatment of antibody-mediated allograft rejection

Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

Chimeric antigen receptor T-cell therapy in autoimmune diseases

High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models

Chimerism-based Tolerance Induction in Clinical Transplantation: Its Foundations and Mechanisms

Chimeric antigen receptor T cell therapy for autoimmune disease

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation

Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer